Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SpyGlass Group
Aliso Viejo, California, United Statesspyglassgroup.co ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SpyGlass Pharma’s IOL-mounted drug delivery platform is designed to provide up to three years of sustained bimatoprost release for patients with glaucoma or ocular hypertension undergoing cataract surgery. In a first-in-human study and a multi-center randomized Phase II trial, the platform demonstrated statistically significant improvements in visual acuity and substantial intraocular pressure reduction at 18 months post-surgery. The company is preparing for pivotal Phase III trials
- Therapeutic areas
- Ophthalmology
- Modalities
- DeviceSmall molecule (bimatoprost)Drug/device combination product
- Industry
- Biotech
Beyond the preview
Go deeper on SpyGlass Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpyGlass Group.